Showing results (221-230 of 236) with videos related to

Sort By:
Pageof 24
Oncotarget|March 1, 2018
Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse modelKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 8, 2019
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
Oncotarget|June 11, 2016
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Murakami, Arun S Singh, Tasuku Kiyuna, et al.
Signal Transduction and Targeted Therapy|May 2, 2018
Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapyKentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, et al.
Heliyon|July 14, 2018
Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutationsKentaro Miyake, Kei Kawaguchi, Masuyo Miyake, et al.
Oncotarget|December 22, 2017
The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapyKentaro Miyake, Takashi Murakami, Tasuku Kiyuna, et al.
Oncotarget|April 14, 2017
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Murakami, Shukuan Li, Qinghong Han, et al.
Biochemical and Biophysical Research Communications|November 6, 2018
Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcomaKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Journal of Cellular Biochemistry|November 17, 2017
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninaseKentaro Igarashi, Shukuan Li, Qinghong Han, et al.
Cancer Letters|January 7, 2018
Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcomaKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Pageof 24